Clinical Trials Logo

Filter by:
NCT ID: NCT03582007 Terminated - Pneumonia Clinical Trials

Pivotal Study in Nosocomial Pneumonia Suspected or Confirmed to be Due to Pseudomonas

PRISM-UDR
Start date: October 22, 2018
Phase: Phase 3
Study type: Interventional

This is a phase 3, multicenter, open-label, sponsor blinded, randomized active-controlled, parallel group to investigate the efficacy, safety and tolerability of intravenous murepavadin given with ertapenem versus an anti-pseudomonal β-lactam based antibiotic in the treatment of nosocomial pneumonia in adult subjects

NCT ID: NCT03581474 Terminated - Atelectasis Clinical Trials

Evaluation of BAL Procedure With Ambu aScope 3 Large in Patients in an ICU Setting

Start date: September 28, 2017
Phase: N/A
Study type: Interventional

An Investigation to determine the single-use scope's ability to suction secretion from the lungs to resolve the collapse of the lung.

NCT ID: NCT03581279 Terminated - Lyme Disease Clinical Trials

Detection of Borrelia Bacteria in Early Stage Lyme Borreliosis Using the T2Lyme Panel

Start date: May 8, 2018
Phase: N/A
Study type: Interventional

The T2Lyme assay will be compared to Borrelia culture from erythema migrans (EM) biopsy and/or detection of the C6 antigen in serum collected prospectively from patients suspected of early Lyme disease.

NCT ID: NCT03581084 Terminated - Asthma Clinical Trials

Inpatient Clinical Trial of NAC

ICON
Start date: July 6, 2018
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine the beneficial effect of n-acetylcysteine (NAC), an inhaled medication that breaks down mucus, on lung function. NAC is a medication approved by the US Food and Drug Administration (FDA) for the treatment of chronic diseases of the respiratory system, including asthma. With CT lung imaging, the investigators seek to identify a subgroup of patients with asthma with a 'mucus' profile. This is a single-arm study which means all participants will receive the same treatment.

NCT ID: NCT03580798 Terminated - Tooth Loss Clinical Trials

Ridge Preservation Comparing Simultaneous vs. Delayed Grafting

Start date: November 8, 2018
Phase: N/A
Study type: Interventional

Comparison of the clinical healing of simultaneous vs. delayed grafting for dental implant placement.

NCT ID: NCT03580694 Terminated - Clinical trials for Carcinoma, Non-Small-Cell Lung

Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Start date: June 27, 2018
Phase: Phase 1
Study type: Interventional

The objective of this trial is to study REGN4659 and cemiplimab in treatment-experienced, non-small cell lung cancer (NSCLC) patients. There are 2 phases of this study: a dose escalation phase and a dose expansion phase.

NCT ID: NCT03580616 Terminated - Clinical trials for Amyotrophic Lateral Sclerosis (ALS)

Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS)

ALS
Start date: October 24, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the tolerability of L-Serine oral doses for ALS patients and assess preliminary indications of efficacy

NCT ID: NCT03580382 Terminated - Melanoma Clinical Trials

Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma

Start date: July 6, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The main goal of this study is to test if it is safe and effective to give CDX-3379 together to treat advanced melanoma in patients with the NRAS mutation and BRAF/NRAS wildtype.

NCT ID: NCT03580044 Terminated - Clinical trials for Serious Bacterial Infection

Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria

Start date: December 25, 2020
Phase: Phase 3
Study type: Interventional

Phase 3 study to determine the efficacy, safety, and tolerability of aztreonam- avibactam (ATM- AVI) versus best available therapy (BAT) in the treatment of hospitalized adults with complicated intra-abdominal infections (cIAI), nosocomial pneumonia (NP) including hospital acquired pneumonia (HAP) and ventilator associated pneumonia (VAP), complicated urinary tract infections (cUTI), or bloodstream infections (BSI) due to metallo-β-lactamase (MBL)- producing Gram-negative bacteria.

NCT ID: NCT03579966 Terminated - Clinical trials for Myasthenia Gravis, MuSK

Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)

Start date: June 11, 2018
Phase: Phase 3
Study type: Interventional

Evaluate the long-term safety of amifampridine phosphate in patients with MuSK antibody positive and AChR antibody positive myasthenia gravis.